cemka > Publications > Infectious

Sort publications on year

  • Pharmaco-Economics

    Economic evaluation of vaccination programmes: a Consensus Statement Focusing on Viral Hepatitis

    BEUTELS P, EDMUNDS WJ, ANTONANZAS F, DE WIT GA, EVANS D, FEILDEN R, FENDRICK AM, GINSBERG GM, GLICK HA, MAST E, PECHEVIS M, VAN DOORSLAER E, BA, VAN HOUT

    Pharmacoeconomics ; 20(1):1-7

  • Pharmaco-Economics

    Cost of Care for Inpatients with Community -Acquired Intra-Abdominal Infections

    CATTAN P, YIN DD, SARFATI E, LYU R, DE ZELICOURT M, FAGNANI F

    Eur J Clin Microbiol Infect Dis ; 21: 787-793

  • Pharmaco-Economics

    Cost and effectiveness of ciprofloxacin + hydrocortisone versus neomycin + polymyxin B + hydrocortisone in France for the treatment of acute otitis externa

    LAFUMA A, FAGNANI F, BERDEAUX G

    Journal of Medical Economics ; 2002;5:11-23

  • Pharmaco - Epidemiology

    Hépavir, première étude observationnelle d’une cohorte de malades traités par interféron alpha-2a en monothérapie

    ROUDOT-THORAVAL F, ABERGEL A, ALLAERT F, BOURLIERE M, DESMORAT H, FAGNANI F, FONTANGES T, HANANA A, POL S, ZARSKI JP, ROUSSEAUX C, GANDOSSI C, ABELSOUR L, DOLE S, DANTIN S, EBERLE F, SAINT-MARC-GIRARDIN MF, Le Groupe d’Etude pour HEpavir

    Gastroenterol Clin Biol ; 2001 (25) : 1061-1066

  • Pharmaco-Economics

    Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era

    CACOUB P, VAUTIER M, DESBOIS AC, LAFUMA A, SAADOUN D

    Liver International ; 2017:37(12):1805-1813

  • Pharmaco - Epidemiology

    An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.

    M LLIBRE J, RAFFI F, MOYLE G, BEHRENS G, BOUEE S, REILLY G, BORG P, PIONTKOWSKY D, ROGATTO F.

    PLoS One - 2016 ; 11 (5)

  • Pharmaco-Economics

    Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals

    LE MONNIER A, DUBURCQ A, ZAHAR JR, CORVEC S, GUILLARD T, CATTOIR V, WOERTHER PL, FIHMAN V, LALANDE V, JACQUIER H, MIZRAHI A, FARFOUR E, MORAND P, MARCADÉ G, COULOMB S, TORRETON E, FAGNANI F, BARBUT F, GMC STUDY GROUP

    J Hosp Infect ; 2015;91:117-122

  • Biometry and database analysis

    Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database

    RAFFI F, YAZDANPANAH Y, FAGNANI F, LAURENDEAU C, LAFUMA A, GOURMELEN J

    J Antimicrob Chemother ; 2015;70:2121-2128

  • Pharmaco-Economics

    Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals

    LE MONNIER A, DUBURCQ A, ZAHAR JR, CORVEC S, GUILLARD T, CATTOIR V, WOERTHER PL, FIHMAN V, LALANDE V, JACQUIER H, MIZRAHI A, FARFOUR E, MORAND P, MARCADÉ G, COULOMB S, TORRETON E, FAGNANI F, BARBUT F, GMC STUDY GROUP

    J Hosp Infect ; 2015;91:117-122

  • Pharmaco-Economics

    A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical

    DEMARTEAU N, DETOURNAY B, TEHARD B, EL HASNAOUI A, STANDAERT B

    Int J Public Health ; 2011;56(2):153-62

  • Pharmaco-Economics

    The cost of managing HIV infection in highly treatment-experienced, HIV-Infected adults in France

    COLIN X, LAFUMA A, COSTAGLIOLA D, LANG JM, GUILLON P

    Pharmacoeconomics ; 2010;28(S1):59-68

  • Public Health and Epidemiology

    Prévac B: prévention de l’hépatite B dans les populations migrantes originaires de zones de forte endémie, Afrique subsaharienne et Asie

    AUBERT JP, CATRICE M, BOUEE S, DI PUMPO A, SANTANA P, GERVAIS A, WAJSBROT A, GELLY J, NOUGAIREDE M

    Revue du Praticien (supplément) ; 2010;60:13-20

  • Pharmaco-Economics

    Modelling the budget impact of Darunavir in the treatment of highly treatment-experienced, HIV-Infected adults in France

    COLIN X, LAFUMA A, COSTAGLIOLA D, SMETS E, MAUSKOPF J, GUILLON P

    Pharmacoeconomics ; 2010;28(S1):183-197

  • Pharmaco-Economics

    Economic impact of use of chlorhexidine-impregnated sponge dressing for prevention of central line-associated infections in the United States

    YE X, RUPNOW M, BASTIDE P, LAFUMA A, OVINGTON L, JARVIS WR

    Am J Infect Control ; 2011;39(8):647-654

  • Pharmaco - Epidemiology

    Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007)

    BOURLIERE M, OUZAN D, ROSENHEIM M, DOFFOËL M, MARCELLIN P, PAWLOTSKY JM, SALOMON L, FAGNANI F, ROUANET S, PINTA A, VRAY M
    SALOMON L, FAGNANI F, ROUANET S, PINTA A, VRAY M

    Antivir Ther ; 2012;17(1):101-110